Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company

Recently, Shanghai Medicilon Inc. (Medicilon) officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).  This collaboration integrates the technical advantages of the three parties in new drug preclinical research, Pre-IND and IND clinical trial applications, clinical trials, and clinical sample analysis. The goal is to enhance and streamline the anti-tumor new drug development industry chain, accelerating the development process of anti-tumor drugs.

Medicilon + Shanghai GoBroad + Start Shanghai
A powerful alliance driving innovation in anti-tumor drug development

Shanghai GoBroad Cancer Hospital focuses on solid tumor oncology, bringing in renowned expert teams from both domestic and international sources. Their services encompass medical care, clinical research, and integrated diagnostics.  The hospital is dedicated to the diagnosis and treatment of complex and severe tumors, clinical research, and the industrial transformation of biomedicine and medical devices. It aims to build a research-oriented hospital organization aligned with international standards and meeting the innovative needs of China's biopharmcatucial industry. The focus is on improving clinical research efficiency and quality, and accelerating the translation of biopharmaceutical innovations.

Start Shanghai Company has a well-established management system for early clinical research of anti-tumor new drugs. Its goal is to build world-class high-level clinical research platforms and centers to accelerate the development process of new anti-tumor drugs in China.  Start Shanghai collaborates with high-level domestic research hospitals or research centers like Shanghai GoBroad through an embedded research center management approach. They provide efficient and professional full-process services for new drug clinical trial site management and have accumulated experience with hundreds of anti-tumor new drug projects.

Medicilon, as a CRO specializing in preclinical biopharmaceutical research, has established advanced technology service platforms in areas such as bispecific antibodies, ADCs, mRNA vaccines, small nucleic acids, PROTACs, and CGT. The company has supported 490 INDs in gaining approval from regulatory authorities like China's NMPA, the US FDA, the EU EMA, and Australia's TGA for clinical trials. In the field of oncology, Medicilon stays aligned with international research trends and has developed over 440 tumor models, accumulating substantial R&D capabilities and experience.

The three parties, based on their deep expertise, technical specialization, and shared vision for the future of oncology drug development, will collaborate to pool and integrate their respective advantages. Together, they aim to advance innovation in anti-tumor drug development.

Preclinical Research + IND Application + Clinical Trials
Deep integration to enhance and streamline the anti-tumor drug industry chain

According to the strategic collaboration agreement, the three parties will closely align with the development needs of new anti-tumor drugs. Leveraging their accumulated experience and technical advantages in oncology drug development, they will ensure seamless integration and efficient collaboration across all stages - from preclinical research and Pre-IND/IND clinical trial applications to clinical trials and clinical sample analysis. This collaboration aims to accelerate the translation of innovative drugs from the laboratory to clinical application, enhancing the overall effectiveness of the anti-tumor drug development industry chain.  Additionally, the three parties will work to deepen their collaboration across multiple dimensions, including technology, market, policy, and regulations. They aim to achieve comprehensive resource sharing and optimal allocation.

It is noteworthy that clinical trial projects recommended by Medicilon to Shanghai GoBroad Cancer Hospital will have Dr. Jin Li, Director of Shanghai GoBroad Cancer Hospital and Lifetime Professor at Shanghai East Hospital of Tongji University, serving as the Principal Investigator (PI). This will provide strong assurance for the successful implementation of the projects.

Each collaboration represents a complement of technical strengths and a convergence of innovative forces. This partnership will not only accelerate the translation of anti-tumor new drugs from the laboratory to clinical settings but also infuse new vitality and hope into the field of cancer treatment both in China and globally.  Medicilon will join forces with more like-minded partners, continuously exploring and innovating at the forefront of anti-tumor new drug development. Together, they aim to drive breakthrough result in the field of oncology drug research and development.

About Shanghai GoBroad Cancer Hospital

Shanghai GoBroad Cancer Hospital specializes in the field of solid tumor research, bringing together renowned experts from both domestic and international sources. Its business scope covers medical services, clinical research, and integrated diagnostics. The hospital is an essential part of GoBroad's innovative medical technology platform.  The hospital will focus on public services in clinical research, aiming to address the diagnosis and treatment of complex and severe tumors, clinical research, and the industrial transformation of biopharmaceuticals and medical devices. It seeks to establish a research-oriented hospital organization that aligns with international standards and meets the innovative needs of China's biopharmaceutical industry. By enhancing the efficiency and quality of clinical research, the hospital aims to accelerate the transformation of innovative biopharmaceutical achievements.  Shanghai GoBroad Cancer Hospital focuses on improving medical efficiency and optimizing patient experience by introducing direct reimbursement systems for municipal medical insurance and commercial insurance. Additionally, it aligns with international medical services to provide patients with a high-quality dual-track medical experience, both domestically and internationally.

About Start Shanghai Company

Founded in Shanghai, START Shanghai was established through joint investment by START (South Texas Accelerated Research Therapeutics), based in San Antonio, Texas, USA, and Cenova Capital.  Since its founding, START (South Texas Accelerated Research Therapeutics) has become the world's largest and most professional independent Phase I clinical research center for anti-cancer drugs. Globally, START operates six clinical research centers, with START Shanghai being the third.

Start Shanghai is introducing the mature management system of START's early-phase clinical research for anti-cancer drugs from the US, drawing on its extensive practical experience. The company aims to build a world-class, high-level clinical research platform and research team, accelerating the development process of anti-cancer drugs in China.

The START research team includes its own operations management, general management, and quality assurance teams, as well as the researchers, nurses, and pharmacists from the research center. The core team members have undergone professional training by START in the US.  Currently, START Shanghai has established embedded partnerships with multiple centers, including Shanghai East Hospital, Shandong Cancer Prevention and Treatment Institute, and the First Affiliated Hospital of Nanchang University. It provides on-site clinical trial management services to large multinational and domestic pharmaceutical companies, as well as small and medium-sized innovative biotechnology companies.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2024, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 490 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.